What is the recommended treatment for influenza B infection?

Treatment of Influenza B

Influenza B should be treated with oseltamivir (75 mg orally twice daily for 5 days in adults) or zanamivir, with oseltamivir preferred for most patients due to ease of administration and broader applicability across patient populations. 1

First-Line Antiviral Agents

Both oseltamivir and zanamivir are neuraminidase inhibitors with proven activity against influenza B and should be initiated as soon as possible, ideally within 48 hours of symptom onset. 1, 2

• Oseltamivir is administered orally at 75 mg twice daily for 5 days in adults and adolescents ≥13 years 2
• Pediatric dosing is weight-based: ≤15 kg receive 30 mg twice daily, >15-23 kg receive 45 mg twice daily, >23-40 kg receive 60 mg twice daily, and >40 kg receive 75 mg twice daily 2
• Zanamivir is delivered by oral inhalation at 10 mg (two 5-mg inhalations) twice daily for 5 days 2

Patient Populations Requiring Immediate Treatment

All hospitalized patients with suspected or confirmed influenza B should receive antiviral therapy immediately, regardless of symptom duration or vaccination status. 2

High-risk groups warranting prompt treatment include:

• Children under 2 years of age, particularly infants under 6 months 2
• Adults ≥65 years 2
• Pregnant women (any trimester) and women within 2 weeks postpartum 2
• Immunocompromised patients, including those on long-term corticosteroids, chemotherapy, or with HIV 2
• Patients with chronic cardiac or respiratory disease (including asthma, COPD, cystic fibrosis) 2
• Patients with diabetes requiring medication, chronic renal disease, chronic liver disease, or neurological disorders 2
• Residents of long-term care facilities 2

Timing Considerations and Late Treatment

While maximum benefit occurs when treatment begins within 48 hours of symptom onset, antiviral therapy should NOT be withheld in high-risk, severely ill, or hospitalized patients presenting beyond 48 hours. 2

• Treatment initiated after 48 hours still provides substantial mortality benefit in hospitalized patients (odds ratio 0.21 for death within 15 days) 2
• High-risk patients benefit from treatment even when initiated up to 96 hours after symptom onset 2
• Otherwise healthy outpatients presenting >48 hours after onset generally do not require treatment unless they develop severe or progressive illness 2

Comparative Efficacy: Oseltamivir vs. Zanamivir for Influenza B

Zanamivir demonstrates superior efficacy compared to oseltamivir specifically for influenza B infection, with significantly shorter duration of fever (35.8 hours vs. 52.7 hours, p<0.001). 3

However, oseltamivir remains the preferred first-line agent for most patients due to practical considerations:

• Zanamivir is contraindicated in patients with underlying airway disease (asthma, COPD) due to risk of bronchospasm 2, 4
• Oral administration of oseltamivir is more practical than inhaled zanamivir, particularly in young children and elderly patients 2
• Oseltamivir can be used across all age groups with appropriate dose adjustment 2

Special Populations and Dosing Adjustments

Patients with renal impairment require dose reduction to prevent drug accumulation and toxicity. 2

Renal dosing adjustments for oseltamivir:

• Creatinine clearance >30-60 mL/min: 30 mg twice daily for treatment 2
• Creatinine clearance 10-30 mL/min: 30 mg once daily for treatment 2
• End-stage renal disease on hemodialysis: 30 mg immediately, then 30 mg after each dialysis session 2

For patients with chronic obstructive pulmonary disease (COPD) or asthma, oseltamivir is strongly preferred over zanamivir to avoid bronchospasm. 2

Expected Clinical Benefits

When initiated within 48 hours, antiviral treatment provides:

• Reduction in illness duration by approximately 1-1.5 days 2
• 50% reduction in risk of pneumonia 2
• 34% reduction in otitis media in children 2
• Significant mortality benefit in hospitalized and high-risk patients 2
• Reduced viral shedding, potentially decreasing transmission 2

Prophylaxis Recommendations

Post-exposure prophylaxis should be considered for high-risk household contacts of influenza B patients, initiated within 48 hours of exposure. 2

• Adults and adolescents ≥13 years: oseltamivir 75 mg once daily for 10 days 4
• Pediatric weight-based dosing: same doses as treatment but given once daily instead of twice daily 4
• Prophylaxis is not a substitute for annual influenza vaccination 2

Common Adverse Effects

The most common side effect of oseltamivir is gastrointestinal upset, with vomiting occurring in approximately 15% of treated children versus 9% on placebo. 2

• Nausea and vomiting are transient and rarely lead to discontinuation 2
• Taking oseltamivir with food reduces gastrointestinal side effects 4
• No established causal link exists between oseltamivir and neuropsychiatric events 2

Critical Pitfalls to Avoid

Do not delay or withhold antiviral treatment while awaiting laboratory confirmation in high-risk patients during influenza season—empiric treatment based on clinical suspicion is appropriate. 2

• Do not withhold treatment solely because symptom onset exceeds 48 hours in hospitalized, severely ill, or high-risk individuals 2
• Do not confuse prophylaxis dosing (once daily) with treatment dosing (twice daily) 4
• Do not use adamantanes (amantadine, rimantadine) for influenza B, as they have no activity against this virus 1

Adjunctive Therapy Considerations

Antibiotics should NOT be routinely added for influenza B unless there is evidence of bacterial superinfection (new consolidation on imaging, purulent sputum, clinical deterioration despite antivirals, or elevated inflammatory markers). 2

• Common bacterial superinfections include S. pneumoniae, S. aureus, and H. influenzae 2
• Corticosteroids are not recommended for influenza B treatment 5